Maze Therapeutics (MAZE) has released its third quarter results, reporting a net loss of US$47.97 million and a basic loss per share of US$0.79 from continuing operations, providing the latest update for investors.
The latest results come after a busy spell for Maze Therapeutics, which recently presented at the Guggenheim Healthcare Innovation Conference. Over the same period, the share price has risen, with a 30-day share price return of 37.77% and a 90-day share price return of 35.14%. Despite that short-term momentum, the stock still shows a year-to-date share price return that is down 7.64%. However, the 1-year total shareholder return of 15.36% indicates that gains have been stronger for investors who stayed in over a longer stretch.
Scan beyond Maze Therapeutics and line up similar stories in the curated 20 high quality undiscovered gems that pair strong fundamentals with potential under the radar momentum.
Maze Therapeutics has already packed in a sharp move over the past month, yet the stock still trades well below analyst targets. Is most of the easy upside gone, or is the rerating only getting started?
Most Popular Narrative: 41% Undervalued
Maze Therapeutics closed at $36.73, while the analyst consensus Narrative on Simply Wall St points to a fair value of $62.55 using a 7.24% discount rate. That gap frames a bullish valuation story that leans heavily on a few specific pipeline and balance sheet assumptions.
A reported cash balance of a little over US$528m and a runway guided into 2029 following a US$150m equity raise provide Maze Therapeutics with funding to complete multiple Phase II trials and initiate a pivotal study, which reduces financing overhang risk and can support smoother R&D execution that may feed into future revenue and margin potential.
See why 1 investors see Maze Therapeutics as 41% undervalued.
Result: Fair Value of $62.55 (UNDERVALUED)
Still, the bullish narrative around Maze Therapeutics can unravel quickly if the ambitious swing from a US$133.6 million loss to positive earnings stalls, or if ongoing equity issuance dilutes future gains.
Find out about the key risks to this Maze Therapeutics narrative.
Another View: Maze Therapeutics On Richer Trading Multiples
The first narrative leans on a fair value of $62.55, yet on simple market ratios Maze Therapeutics is not cheap. The stock trades on a P/B of 4.7x compared with 4.5x for close peers and 1.9x for the wider US Pharmaceuticals group, which raises the question of how much optimism is already in the price.
For anyone weighing that gap, it can help to see how those ratios line up against a fair ratio that the market could eventually move toward, and how much room that leaves for error or opportunity in the current share price story. See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals or a clear skew to optimism, the only way to really judge Maze Therapeutics is to go through the full risk and reward rundown yourself. To weigh the trade off between concerns and upside potential, start with the 1 key reward and 3 important warning signs.
Looking for more investment ideas beyond Maze Therapeutics?
If Maze Therapeutics has sharpened your appetite for opportunity, do not stop here. Use the Simply Wall St screener to uncover fresh stocks with different strengths.
- Target stronger downside protection by focusing on businesses that appear more resilient in tough markets with the help of 30 resilient stocks with low risk scores.
- Hunt for quality at a discount by scanning companies that pair robust fundamentals with seemingly attractive pricing using the 32 high quality undervalued stocks.
- Stack potential income on top of capital returns by reviewing stocks that offer higher yields in the 6 dividend fortresses.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com